For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of this treatment and the formulated version represents a genuine change. These novel therapies preserve the transthyretin protein, preventing its destructive build-up and alleviati